ClinicalTrials.gg
RecruitingNCT06307015DE-RADIATEUpdated Jul 30, 2025

De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)

An interventional study of De-escalation and Standard of care in HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by Royal North Shore Hospital. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Royal North Shore Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hypoxia with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Hypoxia · Australia.

Planned enrollment
6th of 10
25 · median 28
Started
2025
the only one that year
No phase
7 of 10
3 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Royal North Shore Hospital

Among the 10 studies in Hypoxia with a site in Australia, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 7 with no phase, and was the 8th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

3 of the 10 studies in Hypoxia with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hypoxia with a site in Australia, or all of them as a file.
02

Study summary

The goal of this prospective clinical trial is to determine if HPV-associated oropharyngeal squamous cell carcinoma that is non-hypoxic on FMISO PET can be successfully treated with a lower dose of radiation therapy.

The main questions it aims to answer are:

  1. What is the pathologic complete response rate in patients selected for radiation dose de-escalation and neck dissection?
  2. What is the correlation between MRI and FMISO PET assessment of hypoxia before and during RT?
  3. What are the acute and late toxicities in patients selected for radiation dose de-escalation?
  4. What are the quality of life scores in patients selected for radiation dose de-escalation?
  5. What are the local, regional and distant failure rates of patients selected for radiation dose de-escalation?

Patients with cT1-2N1-2b (AJCC 7th edition) oropharyngeal tumours will undergo surgical resection of the primary tumour. Following this, they will be allocated to standard radiation therapy (70Gy with concurrent cisplatin chemotherapy) or de-escalation radiation therapy (30Gy with concurrent cisplatin chemotherapy) based on the results of FMISO PET. Patients with non-hypoxic tumours at baseline OR after two weeks of radiation therapy will be allocated to the de-escalated group. 3-4 months after completion of radiation therapy, all patients in the de-escalated group will undergo mandatory neck dissection to assess pathologic response.

Researchers will assess the pathologic response rate after surgery in the de-escalation group. They will also compare the outcomes (oncological outcomes and quality of life) between the group receiving the standard treatment (70Gy) and the group receiving de-escalated radiation therapy (30Gy).

Read the detailed description

This study is designed to evaluate the role of FMISO PET in selecting patients for de-escalated RT. Patients with cT1-2N-1-2b HPV+ OPC or cTxN1-2 CUP, who are suitable for surgical management of the primary (if applicable) and/or RT to the primary and ipsilateral neck will be included. All patients will undergo surgical resection or core biopsy of the primary site if applicable (negative margins and robotic surgery not mandated) or EUA and tonsillectomy (CUP) and FNA or core biopsy of the cervical lymph node (all patients). Patients will be eligible for inclusion if histopathology is consistent with HPV-associated squamous cell carcinoma or CUP, with p16 positivity (IHC) and HPV positivity (PCR).

Patients enrolled will undergo FMISO PET/CT (after surgery to the primary or EUA/biopsy of suspected primary site) to assess for tumour hypoxia, which will stratify patients into two groups. Determination for the presence or absence of hypoxia will be made on the basis of visual inspection and in accordance with well-established tumour-muscle activity ratio (>1.2) on the late static 18F-FMISO PET by 1 nuclear medicine physician. FMISO PET will be repeat after 5-10 fractions of RT (1-2 weeks of treatment) with the same assessment for hypoxia.

Absence of pre-treatment hypoxia or intra-treatment resolution of hypoxia on FMISO PET will be deemed as an indicator of radiosensitivity and qualify a patient for de-escalation (i.e., to total dose 30Gy). The remainder of patients (i.e., with evidence of tumour hypoxia at the FMISO PET performed after 5-10 fractions of RT) will continue to standard of care RT to a total dose of 70Gy.

Additional MRI images (including T1, T2 and dynamic contract-enhanced and oxygen enhanced sequences) before and during RT (at the same time as 18F FMISO PET). These will not change the patient's management.

All patients will undergo routine FDG-PET/CT scan three months after RT (as part of standard of care). Patients in the de-escalation arm will undergo mandatory ipsilateral neck dissection within 3-4 months of completing RT to assess for pathologic response. Patients will be followed up for a minimum of five years post treatment.

03

Conditions studied

  • HPV Positive Oropharyngeal Squamous Cell Carcinoma

Browse trials for

Keywords

  • Radiation therapy
  • De-escalation
  • FMISO PET
  • Hypoxia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • confirmed cT1-2N1-2b oropharyngeal squamous cell carcinoma or cTxN1-2 carcinoma of unknown primary
  • p16 positive (70% nuclear and cytoplasmic staining) and HPV positive (genotyping via PCR) tumours of the tonsil, base of tongue, glossotonsillar sulcus, or unknown primary site (suspected mucosal origin).
  • No to radiotherapy, platinum-based chemotherapy or surgery
  • No contraindications to PET/CT or MRI
  • (ECOG) performance status score 0-2 ( > 70%)
  • Ability to understand and willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Women lactating, pregnant or of who are not willing to avoid pregnancy during the study
  • Patients with a history of severe renal disease(s) ( \<20) than cannot tolerate gadolinium chelate contrast agents.)
  • ≥ 3
  • Previous high dose radiation therapy to the head or neck
  • Patients unwilling or unable to have PET/CT or MRI
  • Geographically remote patients unable to agree to imaging schedule
  • Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.
  • Patients with significant cardiac or pulmonary disease including cardiac arrythmias or (COPD) that are unable to tolerate high flow O2 for oxygen contrast.
  • Patients taking carbonic anhydrase inhibitors (acetazolamide)
  • History of glaucoma
  • Any implant, foreign body, 3T MRI incompatible device, or other to MRI imaging
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Standard of care

    Standard of care treatment for patients undergoing definitive chemoradiation for oropharyngeal squamous cell carcinoma

    Radiation: Standard of care

  • Experimental
    De-escalation

    De-escalated radiation therapy for patients undergoing surgery to the primary site followed by chemoradiation to the primary site and neck for oropharyngeal squamous cell carcinoma

    Radiation: De-escalation

Interventions

  • RadiationDe-escalation

    Surgical resection of primary oropharyngeal tumour followed by de-escalated radiation therapy (30Gy) with concurrent platinum-based chemotherapy to oropharynx + neck, followed by surgical neck dissection

  • RadiationStandard of care

    Radiation therapy (70Gy) with concurrent platinum-based chemotherapy to oropharynx + neck

06

What researchers measure

Primary outcomes

  1. Pathologic complete response

    Pathologic complete response in surgical neck dissection

    Time frame: 4 months after completion of radiation therapy

Secondary outcomes

  1. Correlation between MRI and FMISO PET assessment of hypoxia

    Correlation between MRI and FMISO PET assessment of hypoxia at baseline and during radiation therapy

    Time frame: Baseline and after 2 weeks of radiation therapy

  2. Quality of Life of patients undergoing de-escalation radiation therapy

    Quality of Life - Global (assessment by EORTC QLQ-30)

    Time frame: Baseline, then 3 months post completion of treatment, then 3-monthly post to 2 years, then 6-monthly to 5 years

  3. Quality of Life of patients undergoing de-escalation radiation therapy

    Quality of Life - Head \& Neck Specific (assessment by EORTC HN-35)

    Time frame: Baseline, then 3 months post completion of treatment, then 3-monthly post to 2 years, then 6-monthly to 5 years

  4. Local control

    Failure rate at primary site (oropharynx) (calculated from date of commencing RT)

    Time frame: 3-monthly to 2 years, 6-monthly to 5 years

  5. Regional control

    Failure rate in neck (calculated from date of commencing RT)

    Time frame: 3-monthly to 2 years, 6-monthly to 5 years

  6. Distant metastases

    Number of participants with radiologically confirmed distant metastases (calculated from date of commencing RT)

    Time frame: 3-monthly to 2 years, 6-monthly to 5 years

  7. Acute toxicities

    Acute toxicities of radiation therapy +/- chemotherapy (assessed by CTCAE V 5.0)

    Time frame: From date of commencement of RT, measured weekly during RT, fortnightly post treatment (up to 3 months post treatment)

  8. Late toxicities

    Acute toxicities of radiation therapy +/- chemotherapy (assessed by CTCAE V 5.0)

    Time frame: Commencing from 3 months post treatment and measured 3-monthly to 2 years, then 6-monthly to 5 years

07

Study locations

1 of 1 sites recruiting
  • Northern Sydney Cancer Centre, Royal North Shore Hospital
    Saint Leonards, New South Wales 2065, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 32 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 12, 2024
StartActual
Apr 1, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2031
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06307015
Lead sponsor
Royal North Shore Hospital
Responsible party
Anna Lawless (Radiation Oncology Fellow & Principal Investigator, Royal North Shore Hospital) — Principal investigator
First posted
Mar 12, 2024
Start date
Apr 1, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2031 (estimated)
Last update
Jul 30, 2025

Study contacts

Heidi Tsang
Contact
heidi.tsang@health.nsw.gov.au
9463 1300
Anna Lawless
principal investigator · Royal North Shore Hospital
Sarah Bergamin
principal investigator · Royal North Shore Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion